Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NovoThirteen

- PMLiVE

Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study

Haemophilia A accounts for up to 85% of the 1,125,000 global haemophilia cases

- PMLiVE

Novo Nordisk to acquire cardiovascular disease specialist Cardior in deal worth over €1bn

The deal includes a candidate being evaluated in a mid-stage trial to treat heart failure patients

- PMLiVE

Novo Nordisk’s Awiqli receives CHMP recommendation to treat diabetes in adults

The chronic disease is estimated to affect 415 million people worldwide

- PMLiVE

Novo Nordisk shares promising phase 3 data for semaglutide in diabetes and chronic kidney disease

An estimated 40% of people living with type 1 or type 2 diabetes will develop CKD in their lifetime

- PMLiVE

Novo Nordisk and Neomorph enter molecular glue degrader partnership worth over $1.4bn

The companies will work on therapies for cardiometabolic and rare diseases

- PMLiVE

Almirall gains rights to Novo Nordisk’s IL-21 blocker for dermatological diseases

NN-8828 has been developed up to phase 2 in non-dermatological indications

- PMLiVE

Rare disease market access – Launching orphan drugs in secondary markets: the Nordic and MENA regions

Join us live at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February, to explore rare disease market access challenges and learn more about these high potential markets.

Mtech Access

- PMLiVE

Novo Nordisk announces two new research collaborations for cardiometabolic diseases

The research programmes will develop novel treatments for obesity and MASH

- PMLiVE

Novo Nordisk’s once-weekly IcoSema shows promise in phase 3a type 2 diabetes trial

IcoSema showed non-inferiority to daily insulin treatment in reducing blood glucose levels

- PMLiVE

Novo Nordisk announces $2.3bn investment to expand production site in France

The investment will increase the manufacturing capacity for Novo's GLP-1 products

- PMLiVE

Novo Nordisk to buy KBP’s hypertension drug ocedurenone for up to $1.3bn

An estimated 1.28 billion adults aged 30 to 79 years worldwide have hypertension

- PMLiVE

Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments

The companies will work together to develop new cardiovascular treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links